Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04081259 · ClinicalTrials.gov registry record · Phase 1

LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy

A Phase 1 study of Acute Myeloid Leukemia, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
Phase 1
Development phase
17
Enrollment target
1
Study location

NCT04081259: Completed Phase 1 study of Acute Myeloid Leukemia, sponsored by Dana-Farber Cancer Institute.

NCT04081259 is a Phase 1 study of Acute Myeloid Leukemia that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 17 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04081259, a Phase 1 study of Acute Myeloid Leukemia, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
Phase 1
Development phase
17 participants
Enrollment target
1
Study location

Study Summary

This research study is evaluating a targeted therapy as a possible treatment for acute myeloid leukemia (AML) that has returned or not responded to standard treatment.

Primary Outcome

Toxicities occurring following administration of protocol therapy, measured using CTCAE 5.0 criteria.

Conditions Studied

Acute Myeloid Leukemia

Interventions

  • DRUG LY3214996

Study Locations (1)

Massachusetts

  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2020-07-15
Est. Completion 2023-08-26
Phase Phase 1
Dana-Farber Cancer Institute

781 total trials

What the finished NCT04081259 record still lists

NCT04081259 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (85% lower).

The record links to 1 condition, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which LY3214996 is the first listed.

NCT04081259 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04081259 about?

NCT04081259 is a clinical study titled "LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy". This research study is evaluating a targeted therapy as a possible treatment for acute myeloid leukemia (AML) that has returned or not responded to standard treatment.

What is the current status of trial NCT04081259?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2020-07-15. Estimated completion is 2023-08-26.

What conditions does trial NCT04081259 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia.

What interventions are being tested in trial NCT04081259?

The interventions under investigation include: LY3214996 (DRUG).

Who is sponsoring clinical trial NCT04081259?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04081259 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04081259's enrollment target sits among peer trials

17 268th of 306 higher than 39 of 306 other Acute Myeloid Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02090140 · 17 participants · NA

    Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects

  • NCT03317860 · 17 participants · NA

    Improving Measurement and Treatment of Post-stroke Neglect

  • NCT04356469 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children

  • NCT04414046 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04081259, the US trial registry maintained by the National Library of Medicine. NCT04081259 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.